Gano Kyle
Gano Kyle, CEO, reported a transaction classified as withholding at NEUROCRINE BIOSCIENCES INC involving 332.000000 shares for an estimated $48505.20. Reported holdings after the transaction were 155010.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Nov 01, 2026
- Filing date
- Nov 03, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
NBIX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- withholding Code F
- Identifier
- 0001567160-26-000011 Common Stock
- Transaction date
- Nov 01, 2026 Filed Nov 03, 2026, 10:59 PM · 2d delay
- Shares
- 332 sh $146.10 per share
- Estimated value
- -$48.5k Computed from shares × price
- Holdings after
- 155,010 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-12 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - tax_withholding-22 points
transaction_code = F
Tax withholding on vesting shares is mechanical.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Executive Officer
- F1
Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
- F2
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F3
This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, vested as to 614 shares on November 1,…
0 other transactions
0 recent txs